

BIBLIOGRAPHY

1. Penault F, Viale G. (2012). Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. *Annals of Oncology*, 23(6), vi19-vi22.
2. Aysola K, Desai A, Welch C, Xu J, Qin Y, et al. (2013). Triple negative breast cancer-an overview. *Hereditary genetics: current research*, 2013(2), 001.
3. Carey L, Dees E, Sawyer L, Gatti L, Moore DT, et al. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clinical cancer research*, 13(8), 2329-2334.
4. Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, et al. (1995). Short course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an Intergroup study. *Journal of clinical oncology*, 13(4), 831-839.
5. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. (2015). Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. *Journal of clinical oncology*, 13(11), 2688-2699.
6. Birgegard G, Apro MS, Bokemeyer C, Dicato M et al. (2005). Cancer-related anemia: Pathogenesis, prevalence, and treatment. *Oncology*, 68(1), 3-11.
7. McCance K, Huether S. (2014). *Pathophysiology: The Biologic Basis for Disease in Adults and Children 3rd Ed*. Missouri: Elsevier.
8. Koris, MA. (2018, July 1). Breast Cancer - Women's Health Issues. Retrieved February 11, 2019, from <https://www.merckmanuals.com/home/women-s-health-issues/breast-disorders/breast-cancer>
9. Sharma G, Dave R, Sanadya J, Sharma P, Sharma K. (2010). Various type and management of breast cancer: an overview. *Journal of advanced pharmaceutical technology & research*, 1(2), 109-126.
10. Lebert J, Lester M, Powell E, Seal M, McCarthy J. (2018). Advances in the systemic treatment of triple-negative breast cancer. *Current oncology*, 25(1), S142-S150.
11. Perou, CM. (2011). Molecular stratification of triple-negative breast cancers. *Oncologist*, 16(1), 61-70.
12. Rakha EA, Reis-Filho JS, Ellis IO. (2008). Basal-like breast cancer: a critical review. *Journal of clinical oncology*, 26(15), 2568-2581.
13. Bertrucci F, Finetti P, Cervera N, Esterni B, Hermitte F, et al. (2008). How basal are triple negative breast cancers?. *International Journal of Cancer*, 123(1), 236-240.
14. Foulkes WD, Smith IE, Reis-Filho JS,. (2010). Triple-negative breast cancer. *New England journal of medicine*, 363, 1938-1948.
15. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne Ck, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. (2015). Comprehensive genomic analysis identifies novel

- subtypes and targets of triple-negative breast cancer. *Clinical cancer research*, 21(7), 1688-1698.
16. Richardson AL, Wang ZC, De Nicolo A, et al. (2006). X chromosomal abnormalities in basal-like human breast cancer. *Cancer cell*, 9(2), 121-132.
 17. Foulkes WD, Stefanson IM, Chappuis PO, Begin LR, Goffin JR, et al. (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. *Journal of national cancer institute*, 95(19), 1482-1485.
 18. Criscitiello C, Azim HA, Jr, Schouten PC, Linn SC, Sotiriou C. (2012). Understanding the biology of triple-negative breast cancer. *Annals of oncology*, 23(6), vi13-vi18.
 19. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. *Genome biology*, 8(8), 157-174.
 20. Rouzier R, Perou CM, Symmans WF, et al. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clinical cancer research*, 11(16), 5678-5685.
 21. Nielsen D, Dombernowsky P, Larsen SK, et al. (2000). Epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. *Cancer chemotherapy pharmacology*, 46(6), 459-466.
 22. Smith IC, Heys SD, Hutcheon AW et al. (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. *Journal of clinical oncology*, 20(6), 1456-1466.
 23. Buzdar AU, Singletary SE, Theriault RL et al. (1999). Prospective evaluation of paclitaxel versus combination chemotherapy with fluororacil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. *Journal of clinical oncology*, 17(11), 3412-3417.
 24. Joensuu H, Gligorov J. (2012). Adjuvant treatments for triple-negative breast cancers. *Annals of oncology*, 23(6), vi40-vi45.
 25. Carey LA, Rugo HS, Marcom PK. (2008). EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. *Journal of clinical oncology*, 26(15), 1009-1009.
 26. Fischbach F, Dunning M. (2015). *A Manual of Laboratory and Diagnostic Tests 9th Ed.* Philadelphia: Lipincott Williams & Wilkins.
 27. Dicato M, Plawny L, Diederich M. (2010). Anemia in cancer. *Annals of oncology*, 21(7), vii167-vii172.
 28. Morceau F, Dicato M, Diederich M. (2010). Pro-inflammatory cytokine mediated anemia: regarding molecular mechanism of erythropoiesis. *Mediators Inflammation*, 2009, 405016.
 29. Alter BP. (2007). Diagnosis, genetics, and management of inherited bone marrow failure syndromes. *American society of hematology education program*, 2007, 29-39.
 30. Andreassen PR, D'Andra AD, Taniguchi T. (2004). ATR couples FANCD2 monoubiquitination to the DNA-damage response. *Genes development*, 18(16), 1958-1963.

31. NCCN clinical practice guidelines, *Cancer and chemotherapy induced anemia*, V2, 2010. Available at http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf
32. Groopman J, Itri L. (2000). Chemotherapy-induced anemia in adults: incidence and treatment. *Journal of national cancer institute*, 92(6), 1616-1634.
33. Caro J, Salas M, Ward A, Goss G. (2001), Anemia as an independent prognostic factor for survival in patients with cancer. *American cancer society*, 91(12), 2214-2221.
34. McKenzie S, Williams J. (2016). *Clinical Laboratory Hematology 3rd Ed*. Edinburgh: Pearson Education Limited.
35. Oba K, Paoletti S, Alberts S, Bang YJ, Benedetti J, et al. (2013). Disease Free Survival as Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta Analysis. *Journal of the National Cancer Institute*, 105(21), 1600-1607.
36. Chua YJ, Sargent D, Cunningham D. (2005). Definition of disease-free survival: this is my truth-show me yours. *Annals of Oncology*, 16(11), 1719-1721.
37. U.S. Department of Health and Human Services Food and Drug Administration Clinical Trials Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry, 2018. Available at <https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf>
38. Sparano, JA. (2018, December 7). TNM Classification for Breast Cancer. *Medscape*. Diakses dari <https://emedicine.medscape.com/article/2007112-overview#a1>
39. Chen B, Dai D, Tang H, Ai X, Chen X, Zhang X, Li Z, Xie X. (2016) Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. *PLoS ONE* 11(11): e0165133. doi:10.1371/journal.pone.0165133
40. Mcguire, A. et al., 2015. Effects of Age on the Detection and Management of Breast Cancer. *Cancers*, 7(2), pp.908–929.
41. Bottini, A., Berruti, A., Brizzi, M., Bersiga, A., Generali, D., Allevi, G., Aguggini, S., Bolsi, G., Bonardi, S., Bertoli, G., Alquati, P. and Dogliotti, L., 2003. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. *British Journal of Cancer*, 89(6), pp.977-982.
42. Schober, P. and Vetter, T., 2018. Survival Analysis and Interpretation of Time-to-Event Data. *Anesthesia & Analgesia*, 127(3), pp.792-798.
43. Toikkanen, S., Pylkkänen, L. and Joensuu, H., 1997. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. *British Journal of Cancer*, 76(9), pp.1234-1240.
44. Gonçalves, H., Guerra, M., Duarte Cintra, J., Fayer, V., Brum, I. and Bustamante Teixeira, M., 2018. Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort. *Clinical Medicine Insights: Oncology*, 12, p.117955491879056.

45. Sun, L., Zhu, Y., Qian, Q. and Tang, L., 2018. Body mass index and prognosis of breast cancer. *Medicine*, 97(26), p.e11220.
46. Han, Y., Yu, Z., Wen, S., Zhang, B., Cao, X. and Wang, X., 2011. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. *Breast Cancer Research and Treatment*, 131(2), pp.483-490.
47. Poggi, M., Danforth, D., Sciuto, L., Smith, S., Steinberg, S., Liewehr, D., Menard, C., Lippman, M., Lichter, A. and Altemus, R., 2003. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy. *Cancer*, 98(4), pp.697-702.
48. Freedman GM, Anderson PR, LiT, Nicolaou N. Local-Regional Recurrence of Triple Negative Breast Cancer after Breast-Conserving Surgery and Radiation. 2009. *Cancer* ;115:946-951
49. Varlotto J, Stevenson M. Anemia, tumor hypoxemia, and the cancer patient. 2005. *International Journal of Radiation Oncology, Biology, Physics*. 63(1), pp. 25-36.
50. Costa R, Gradishar W. Triple-Negative Breast Cancer: Current Practice and Future Directions. 2017. *Journal of Oncology Practice*. 13(5):301-303.
51. Busti, F., Marchi, G., Ugolini, S., Castagna, A., & Girelli, D. 2018. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. *Pharmaceuticals (Basel, Switzerland)*, 11(4), pp. 94. <https://doi.org/10.3390/ph11040094>
52. Zhang, J., Wu, Y., Lin, Y. H., Guo, S., Ning, P. F., Zheng, Z. C., Wang, Y., & Zhao, Y. 2018. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer. *World journal of gastroenterology*, 24(22), pp. 2381–2391. <https://doi.org/10.3748/wjg.v24.i22.2381>
53. Huang, Y., Wei, S., Jiang, N. *et al.* 2018. The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis. *BMC Cancer* **18**, pp. 1235. <https://doi.org/10.1186/s12885-018-5136-5>
54. Crawford, J., Cella, D., Cleeland, C.S., Cremieux, P.-Y., Demetri, G.D., Sarokhan, B.J., Slavin, M.B. and Glaspy, J.A. 2002. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. *Cancer*, 95, pp.888-895. doi:[10.1002/cncr.10763](https://doi.org/10.1002/cncr.10763)
55. Kypriotakis, G., Vidrine, D. J., Francis, L. E., & Rose, J. H. 2016. The longitudinal relationship between quality of life and survival in advanced stage cancer. *Psycho-oncology*, 25(2), pp. 225–231. <https://doi.org/10.1002/pon.3846>
56. Schito, L. and Semenza, G., 2016. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. *Trends in Cancer*, 2(12), pp.758-770.
57. Lee, C. L., Tsai, C. H., Yeh, D. C., Lin, C. S., Li, Y. F., & Tzeng, H. E. 2017. Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer. *Oncotarget*, 8(1), pp. 1569–1579. <https://doi.org/10.18632/oncotarget.13679>



UNIVERSITAS
GADJAH MADA

Predictive Value Of Pre-Chemotherapy Anemia To Triple Negative Breast Cancer Patients Survival In Tulip Cancer Center Sardjito Hospital
MIFTHA FADHILLA A S, Dr. dr. Ibnu Purwanto, Sp.PD, KHOM; dr. Mardiah Suci Hardianti, Sp.PD, Ph.D-KHOM
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

58. Cata, J. P., & Gottumukkala, V. 2014. Blood transfusion practices in cancer surgery. *Indian journal of anaesthesia*, 58(5), pp. 637–642.
<https://doi.org/10.4103/0019-5049.144675>